OBJECTIVES: Although apolipoprotein E (APOE) genetic variation may influence risk of gait decline and disability in aging through multiple mechanisms, a systematic examination of this relationship has been lacking. Our objective was to quantify the risk of gait decline and disability associated with the APOE ε4 allele in aging. METHODS: We evaluated 627 community-dwelling adults aged 70 and older (white 67.8%) with APOE genotype and quantitative gait measurements participating in the Einstein Aging Study over a median follow-up of 3.0 years. Main outcomes were gait speed decline (cm/s/year) and incident disability. RESULTS: APOE ε4 allele frequency was 24.1%. Presence of APOE ε4 was not significantly associated with gait speed decline overall (p = .37) but was associated with faster gait speed decline in older men (estimate: -1.16, 95% CI: -2.31 to -0.01, p = .04). The interaction between the ε4 allele and male sex predicted gait speed decline (estimate: -1.70, 95% CI: -3.33 to -0.07, p = .04). Presence of the APOE ε4 allele was associated with increased risk of disability in older men (HR 3.72, 95% CI: 1.44-9.59, p = .007). Associations of the ε4 allele with study outcomes remained significant even after accounting for several potential confounders including vascular and cognitive status. The strength of the associations was stronger in the white subgroup. CONCLUSION: This preliminary report suggests that the APOE ε4 allele is associated with increased risk of gait speed decline and disability in older men.
OBJECTIVES: Although apolipoprotein E (APOE) genetic variation may influence risk of gait decline and disability in aging through multiple mechanisms, a systematic examination of this relationship has been lacking. Our objective was to quantify the risk of gait decline and disability associated with the APOE ε4 allele in aging. METHODS: We evaluated 627 community-dwelling adults aged 70 and older (white 67.8%) with APOE genotype and quantitative gait measurements participating in the Einstein Aging Study over a median follow-up of 3.0 years. Main outcomes were gait speed decline (cm/s/year) and incident disability. RESULTS:APOE ε4 allele frequency was 24.1%. Presence of APOE ε4 was not significantly associated with gait speed decline overall (p = .37) but was associated with faster gait speed decline in older men (estimate: -1.16, 95% CI: -2.31 to -0.01, p = .04). The interaction between the ε4 allele and male sex predicted gait speed decline (estimate: -1.70, 95% CI: -3.33 to -0.07, p = .04). Presence of the APOE ε4 allele was associated with increased risk of disability in older men (HR 3.72, 95% CI: 1.44-9.59, p = .007). Associations of the ε4 allele with study outcomes remained significant even after accounting for several potential confounders including vascular and cognitive status. The strength of the associations was stronger in the white subgroup. CONCLUSION: This preliminary report suggests that the APOE ε4 allele is associated with increased risk of gait speed decline and disability in older men.
Authors: Aron S Buchman; Patricia A Boyle; Robert S Wilson; Todd L Beck; Jeremiah F Kelly; David A Bennett Journal: Alzheimer Dis Assoc Disord Date: 2009 Jan-Mar Impact factor: 2.703
Authors: Amy E Sanders; Cuiling Wang; Mindy Katz; Carol A Derby; Nir Barzilai; Laurie Ozelius; Richard B Lipton Journal: JAMA Date: 2010-01-13 Impact factor: 56.272
Authors: Aladdin H Shadyab; JoAnn E Manson; Wenjun Li; Margery Gass; Robert L Brunner; Michelle J Naughton; Brad Cannell; Barbara V Howard; Andrea Z LaCroix Journal: Age Ageing Date: 2018-11-01 Impact factor: 10.668
Authors: Joe Verghese; Cedric Annweiler; Emmeline Ayers; Nir Barzilai; Olivier Beauchet; David A Bennett; Stephanie A Bridenbaugh; Aron S Buchman; Michele L Callisaya; Richard Camicioli; Benjamin Capistrant; Somnath Chatterji; Anne-Marie De Cock; Luigi Ferrucci; Nir Giladi; Jack M Guralnik; Jeffrey M Hausdorff; Roee Holtzer; Ki Woong Kim; Paul Kowal; Reto W Kressig; Jae-Young Lim; Susan Lord; Kenichi Meguro; Manuel Montero-Odasso; Susan W Muir-Hunter; Mohan L Noone; Lynn Rochester; Velandai Srikanth; Cuiling Wang Journal: Neurology Date: 2014-07-16 Impact factor: 9.910
Authors: Amelia J Anderson-Mooney; Frederick A Schmitt; Elizabeth Head; Ira T Lott; Kenneth M Heilman Journal: Brain Cogn Date: 2016-02-27 Impact factor: 2.310
Authors: Neelesh K Nadkarni; Subashan Perera; Beth E Snitz; Chester A Mathis; Julie Price; Jeff D Williamson; Steven T DeKosky; William E Klunk; Oscar L Lopez Journal: JAMA Neurol Date: 2017-01-01 Impact factor: 18.302